[Effect of the sulfonylurea HB 419 (glibenclamide), tolbutamide and tolazamide on the lipolysis of isolated human fat cells].
D000273:Adipose Tissue / Q000378:metabolism*; D003864:Depression, Chemical; D005223:Fats / Q000378:metabolism*; D005990:Glycerol / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D066298:In Vitro Techniques; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D014042:Tolazamide / Q000008:administration & dosage / Q000494:pharmacology; D014044:Tolbutamide / Q000008:administration & dosage / Q000494:pharmacology*; D014508:Urea / Q000494:pharmacology*
D005223:Fats; D007004:Hypoglycemic Agents; D007328:Insulin; D014508:Urea; D014044:Tolbutamide; D014042:Tolazamide; D005990:Glycerol; D009638:Norepinephrine
Die Wirkung von Sulfonylharnstoffen HB 419 (Glibenclamid), Tolbutamid und Tolazamid auf die Lipolyse isolierter menschlicher Fettzellen.